Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Study of RV521 in Infants With RSV Lower Respiratory Tract Infection (REVIRAL 1)
2018-001010-15Phase 2Terminated
- Sponsor
- ReViral
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sisunatovir in respiratory syncytial virus disease (RSV) (3 arms), sponsored by ReViral. Primary endpoint: Safety and tolerability of RV521. Started Nov 2018; status: terminated.
02
Drugs
sisunatovir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2018-001010-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001010-15.